Germany-based pharmaceutical company Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp, a Florida-based contract development and manufacturing organisation (CDMO) and radiopharmacy solutions provider, on Thursday announced the expansion of a strategic partnership and licensing agreement to produce and distribute Neuraceq from PharmaLogic's PET radiopharmaceutical manufacturing facility located near Salt Lake City, Utah.

The first commercial doses were made available on 23 April 2025.

Neuraceq is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterisation of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrolment in clinical trials to further support drug development in neurodegenerative diseases.

Neuraceq is an adjunct to other diagnostic evaluations.